Clinical Study of Glaukos® Trabecular Micro-Bypass System Model iS3 Infinite Vs. Competitor
← catalyst calendarSponsored by Glaukos Corporation (industry) · GKOS — their whole pipeline →.
Phase
Not applicable
Status
Active, not recruiting
Study type
Interventional
Design
Randomized · Double · Treatment
Enrollment
179actual
Sites
1
Country
Canada
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2021-11-27 | actual | When the study began enrolling |
| Primary completion | 2024-02-29 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-02-28 | estimated | The whole study's end, after follow-up |
| First posted | 2021-11-19 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2024-08-15 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Glaucoma
- Glaucoma, Open-Angle
Interventions
- Device: iStent Infinite
- Device: Competitor Device
Primary outcome
what the primary-completion date above is the date OFChange in Mean Diurnal Intraocular Pressure
measured Month 24
Publications
- PMID 40128494 — linked by the registry
Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.
Permalink · GKOS's whole pipeline · Catalyst calendar · Every registered study · What changed